News Focus
News Focus
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

Re: Democritus_of_Abdera post# 2033

Sunday, 08/10/2008 1:14:59 PM

Sunday, August 10, 2008 1:14:59 PM

Post# of 2446
When the dust settles, Lucentis/Avastin will IMO end up being part of the SoC for DME.

In the redesigned trial, MRK should include an arm testing Lucentis/Avastin + I-vation as well as an arm testing Lucentis/Avastin monotherapy; if they don’t, they incur the risk of achieving a successful outcome in the trial that is all but meaningless from a business standpoint.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SRDX News